Xtandi meets in chemotherapy-naïve CRPC patients

13:48 EDT 22 Oct 2013 | BioCentury

Medivation Inc. (NASDAQ:MDVN) and partner Astellas Pharma Inc. (Tokyo:4503) stopped early the Phase III PREVAIL trial on the recommendation of an independent DMC after an interim analysis showed enzalutamide met the co-primary endpoints in chemothera...

Original Article: Xtandi meets in chemotherapy-naïve CRPC patients

NEXT ARTICLE

More From BioPortfolio on "Xtandi meets in chemotherapy-naïve CRPC patients"

Search BioPortfolio:
Advertisement
Advertisement

Searches Linking to this Story